All patients | CTC positive | CTC negative | ||||||
---|---|---|---|---|---|---|---|---|
Number | Percent | Number | Percent | Number | Percent | P-value* | ||
Number: | 733 | 100% | 58 | 7.9% | 675 | 92.1% | ||
Age: | < 35 | 15 | 2.0% | 1 | 1.7% | 14 | 2.1% | 0.503 |
35 to 45 | 89 | 12.1% | 10 | 17.2% | 79 | 11.7% | ||
45 to 55 | 203 | 27.7% | 18 | 31.0% | 185 | 27.4% | ||
> 55 | 426 | 58.1% | 29 | 50.0% | 397 | 58.8% | ||
Tumour size: | pT1 (< 2.0 cm) | 405 | 55.3% | 30 | 51.7% | 375 | 55.6% | 0.373§ |
pT2 (2.0 to 5.0 cm) | 225 | 30.7% | 20 | 34.5% | 205 | 30.4% | ||
pT3 (> 5.0 cm) | 2 | 0.3% | 2 | 3.4% | 0 | 0% | ||
pTX | 60 | 8.2% | 3 | 5.2% | 57 | 8.4% | ||
Histological grade: | Grade 1 | 187 | 25.5% | 9 | 15.5% | 178 | 26.4% | 0.186 |
Grade 2 | 350 | 47.7% | 29 | 50.0% | 321 | 47.6% | ||
Grade 3 | 186 | 25.4% | 18 | 31.0% | 168 | 24.9% | ||
Unknown | 10 | 1.4% | 2 | 3.4% | 8 | 1.2% | ||
ER status: | Positive | 516 | 70.4% | 31 | 53.4% | 485 | 71.9% | 0.002 |
Negative | 179 | 24.4% | 24 | 41.4% | 155 | 23.0% | ||
Unknown | 38 | 5.2% | 3 | 5.2% | 35 | 5.2% | ||
PR status: | Positive | 401 | 54.7% | 25 | 43.1% | 376 | 55.7% | 0.046 |
Negative | 288 | 39.3% | 30 | 51.7% | 258 | 38.2% | ||
Unknown | 44 | 6.0% | 3 | 5.2% | 41 | 6.1% | ||
HER2 status: | Positive | 83 | 11.3% | 15 | 25.9% | 68 | 10.1% | < 0.001 |
Negative | 610 | 83.2% | 40 | 69.0% | 570 | 84.4% | ||
Unknown | 40 | 5.5% | 3 | 5.2% | 37 | 5.5% | ||
Node status: | pN0 | 483 | 65.9% | 34 | 58.6% | 449 | 66.5% | 0.089 |
pN1 | 150 | 20.5% | 11 | 19.0% | 139 | 20.6% | ||
pN2 | 53 | 7.2% | 9 | 15.5% | 44 | 6.5% | ||
pN3 | 22 | 3.0% | 3 | 5.2% | 19 | 2.8% | ||
pNX | 25 | 3.4% | 1 | 1.7% | 24 | 3.6% | ||
Vascular invasion: | Yes | 116 | 15.8% | 12 | 20.7% | 104 | 15.4% | 0.171 |
No | 524 | 71.5% | 35 | 60.3% | 489 | 72.4% | ||
Unknown | 93 | 12.7% | 11 | 19.0% | 82 | 12.1% | ||
Bone marrow status: | Positive | 86 | 11.7% | 17 | 29.3% | 69 | 10.2% | < 0.001 |
Negative | 605 | 82.5% | 35 | 60.3% | 570 | 84.4% | ||
Unknown | 42 | 5.7% | 6 | 10.3% | 36 | 5.3% | ||
Adjuvant systemic treatment: | No treatment | 391 | 53.3% | 28 | 48.3% | 363 | 53.8% | 0.392 |
Chemo +/- Hormonal | 155 | 21.1% | 16 | 27.6% | 139 | 20.6% | ||
Hormonal therapy Only | 164 | 22.4% | 11 | 19.0% | 153 | 22.7% | ||
Unknown | 23 | 3.1% | 3 | 5.2% | 20 | 3.0% | ||
Metastasis: | Number | 149 | 20.3% | 22 | 37.9% | 127 | 18.8% | 0.001 |
Median time to event | 36.4 months | 30.8 months | 37.2 months | |||||
Median followup time | 84.3 months | 78.6 months | 85.2 months | |||||
Breast cancer-specific deaths: | Number | 122 | 16.6% | 19 | 32.8% | 103 | 15.3% | < 0.001 |
Median time to event | 42.9 months | 54.3 months | 42.0 months | |||||
Median followup time | 99.2 months | 94.1 months | 99.2 months |